The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1671
March 6, 2023
View Complete Issue         Table of Contents 2019 
Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence
March 6, 2023 (Issue: 1671)
The FDA has approved Rebyota (Ferring), a rectally-administered, live fecal microbiota suspension, for prevention of additional recurrences of Clostridioides difficile infection (CDI) following antibiotic treatment for a recurrent episode of CDI...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence
Article code: 1671b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.